SCHEMBL4330711

SCHEMBL4330711

CN(C)[C@@H]1CCN(c2cc(N3CCN(c4ccccc4Cl)CC3)c(F)cc2C=NNC(N)=S)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.40
WDR5 P61964 1/20 0.38
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
MYC P01106 1/20 0.35
MAPT P10636 5/20 0.35
ALDH1A1 P00352 4/20 0.35
HTT P42858 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALOX12 P18054 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
FPR1 P21462 1/20 0.35
FPR2 P25090 1/20 0.35
GAA P10253 5/20 0.34
KDM4E B2RXH2 2/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4330708 1.00 MAOB (0.40) MAOBWDR5PIM1PIM3PIM2
SCHEMBL4327291 0.94 MAOB (0.36) MAOBWDR5MAPTALDH1A1HTT
SCHEMBL4327294 0.94 MAOB (0.36) MAOBWDR5MAPTALDH1A1HTT
SCHEMBL4327443 0.93 MAOB (0.44) MAOBPIM1PIM3PIM2MYC
SCHEMBL4327449 0.93 MAOB (0.44) MAOBPIM1PIM3PIM2MYC
SCHEMBL4331451 0.91 MAOB (0.40) MAOBPIM1PIM3PIM2MYC
SCHEMBL4331454 0.91 MAOB (0.40) MAOBPIM1PIM3PIM2MYC
SCHEMBL4331695 0.90 MAOB (0.41) MAOBWDR5PIM1PIM3PIM2
SCHEMBL4331693 0.90 MAOB (0.41) MAOBWDR5PIM1PIM3PIM2
SCHEMBL4336711 0.90 MAOB (0.39) MAOBWDR5PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885WDR5 4272/4885PIM1 2890/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 3093/4885WDR5 3954/4885PIM1 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.